https://orcid.org/0000-0002-1895-4895
References
- Michalek IM, Loring B, John SM. Global Report on Psoriasis. World Health Organization. 2016.
- Langley RGB. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18–ii23.
- Kumar S, Nayak C, Padhi T, et al. Epidemiological pattern of psoriasis, vitiligo and atopic dermatitis in India: hospital-based point prevalence. Indian Dermatol Online J. 2014;5:6.
- Vafaei SY, Dinarvand R, Esmaeili M, et al. Controlled-release drug delivery system based on fluocinolone acetonide-cyclodextrin inclusion complex incorporated in multivesicular liposomes. Pharm Dev Technol. 2015;20:775–781.
- Pradhan M, Singh D, Murthy SN, et al. Design, characterization and skin permeating potential of fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids. 2015;101:56–63.
- D’souza J, More H. Topical anti-inflammatory gels of fluocinolone acetonide entrapped in eudragit based microsponge delivery system. Res J Pharm Tech. 2008;1:502–506.
- Fluocinolone acetonide. http://www.drugbank.ca/drugs/DB00591.
- Kumar R, Katare OP. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review. AAPS PharmSciTech. 2005;6:E298–E310.
- Sharma R, Gupta P, Yadav A. Organogels: a review. Int J Res Pharm Life Sci. 2013;1:125–130.
- Vintiloiu A, Leroux J-C. Organogels and their use in drug delivery – a review. J Control Release. 2008;125:179–192.
- Hashizaki; Saito Y. Taguchi. Lecithin – organogel forming agent. EP2787050A1.
- Boddu SHS, Alsaab H, Umar S, et al. Anti-inflammatory effects of a novel ricinoleic acid poloxamer gel system for transdermal delivery. Int J Pharm. 2015;479:207–211.
- Morales ME, Clarés B, López-Viota M, et al. Preparation, characterization, and in vitro release of new transdermal methimazole as alternative to oral delivery. Drug Deliv. 2009;16:1–10.
- Bhatia A, Singh B, Raza K, et al. Tamoxifen-loaded lecithin organogel (LO) for topical application: development, optimization and characterization. Int J Pharm. 2013;444:47–59.
- Gonjari ID, Karmarkar AB, Kasture PV. In vitro evaluation of different transnasal formulations of sumatriptan succinate: a comparative analysis. Drug Discov Ther. 2009;3:266–271.
- Hadidi N, Nazari N, Aboofazeli R. Formulation and optimization of microemulsion- based organogel containing propranolol hydrochloride using experimental design methods. DARU J Pharm Sci. 2009;17:217–224.
- Pisal S, Shelke V, Mahadik K, et al. Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride. AAPS PharmSciTech. 2004;5:e63.
- Singh S, Parhi R, Garg A. Formulation of topical bioadhesive gel of aceclofenac using 3-level factorial design. Iran J Pharm Res. 2011;10:435–445.
- Agrawal V, Gupta V, Ramteke S, et al. Preparation and evaluation of tubular micelles of pluronic lecithin organogel for transdermal delivery of sumatriptan. AAPS PharmSciTech. 2010;11:1718–1725.
- Yeligar V. Organogel: factors and its importance. Int J Biol Chem Sci. 2014;4:758–773.
- Mandal S, Mandal SS, Sawant K. Lecithin stabilized organogel: design and development for topical application of clobetasol propionate. Int J Pharm Tech Res. 2010;2:1133–1138.
- Gupta A, Nayak K, Misra M. Cow ghee fortified ocular topical microemulsion; in vitro, ex vivo, and in vivo evaluation. J Microencapsul. 2019;36:603–621.
- Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–133.